vs
Pacira BioSciences, Inc.（PCRX）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是Pacira BioSciences, Inc.的1.8倍（$324.4M vs $177.4M），Revolve Group, Inc.净利率更高（5.7% vs 1.6%，领先4.1%），Revolve Group, Inc.同比增速更快（10.4% vs 5.0%），过去两年Revolve Group, Inc.的营收复合增速更高（9.5% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
PCRX vs RVLV — 直观对比
营收规模更大
RVLV
是对方的1.8倍
$177.4M
营收增速更快
RVLV
高出5.4%
5.0%
净利率更高
RVLV
高出4.1%
1.6%
两年增速更快
RVLV
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $324.4M |
| 净利润 | $2.9M | $18.6M |
| 毛利率 | — | 53.3% |
| 营业利润率 | 3.9% | 6.3% |
| 净利率 | 1.6% | 5.7% |
| 营收同比 | 5.0% | 10.4% |
| 净利润同比 | — | 50.4% |
| 每股收益（稀释后） | $0.07 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRVLV
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $324.4M | ||
| Q3 25 | $179.5M | $295.6M | ||
| Q2 25 | $181.1M | $309.0M | ||
| Q1 25 | $168.9M | $296.7M | ||
| Q4 24 | $187.3M | $293.7M | ||
| Q3 24 | $168.6M | $283.1M | ||
| Q2 24 | $178.0M | $282.5M |
净利润PCRXRVLV
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $18.6M | ||
| Q3 25 | $5.4M | $21.2M | ||
| Q2 25 | $-4.8M | $10.2M | ||
| Q1 25 | $4.8M | $11.8M | ||
| Q4 24 | — | $12.3M | ||
| Q3 24 | $-143.5M | $11.0M | ||
| Q2 24 | $18.9M | $15.4M |
毛利率PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 53.3% | ||
| Q3 25 | 80.9% | 54.6% | ||
| Q2 25 | 77.4% | 54.1% | ||
| Q1 25 | 79.7% | 52.0% | ||
| Q4 24 | 78.7% | 52.5% | ||
| Q3 24 | 76.9% | 51.2% | ||
| Q2 24 | 75.1% | 54.0% |
营业利润率PCRXRVLV
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 6.3% | ||
| Q3 25 | 3.5% | 7.1% | ||
| Q2 25 | 4.7% | 5.8% | ||
| Q1 25 | 1.2% | 5.0% | ||
| Q4 24 | 13.2% | 3.9% | ||
| Q3 24 | -82.8% | 5.0% | ||
| Q2 24 | 15.9% | 5.8% |
净利率PCRXRVLV
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 5.7% | ||
| Q3 25 | 3.0% | 7.2% | ||
| Q2 25 | -2.7% | 3.3% | ||
| Q1 25 | 2.8% | 4.0% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | -85.1% | 3.9% | ||
| Q2 24 | 10.6% | 5.4% |
每股收益（稀释后）PCRXRVLV
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.27 | ||
| Q3 25 | $0.12 | $0.29 | ||
| Q2 25 | $-0.11 | $0.14 | ||
| Q1 25 | $0.10 | $0.16 | ||
| Q4 24 | $0.38 | $0.18 | ||
| Q3 24 | $-3.11 | $0.15 | ||
| Q2 24 | $0.39 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $292.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $512.5M |
| 总资产 | $1.2B | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRVLV
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $292.3M | ||
| Q3 25 | $246.3M | $315.4M | ||
| Q2 25 | $445.9M | $310.7M | ||
| Q1 25 | $493.6M | $300.8M | ||
| Q4 24 | $484.6M | $256.6M | ||
| Q3 24 | $453.8M | $252.8M | ||
| Q2 24 | $404.2M | $244.7M |
总债务PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXRVLV
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $512.5M | ||
| Q3 25 | $727.2M | $490.2M | ||
| Q2 25 | $757.8M | $468.6M | ||
| Q1 25 | $798.5M | $453.4M | ||
| Q4 24 | $778.3M | $437.8M | ||
| Q3 24 | $749.6M | $420.8M | ||
| Q2 24 | $879.3M | $405.8M |
总资产PCRXRVLV
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $765.0M | ||
| Q3 25 | $1.3B | $751.3M | ||
| Q2 25 | $1.5B | $722.9M | ||
| Q1 25 | $1.6B | $713.9M | ||
| Q4 24 | $1.6B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.6B | $657.8M |
负债/权益比PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-13.3M |
| 自由现金流率自由现金流/营收 | — | -4.1% |
| 资本支出强度资本支出/营收 | — | 1.0% |
| 现金转化率经营现金流/净利润 | — | -0.55× |
| 过去12个月自由现金流最近4个季度 | — | $48.0M |
8季度趋势，按日历期对齐
经营现金流PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-10.2M | ||
| Q3 25 | $60.8M | $11.8M | ||
| Q2 25 | $12.0M | $12.6M | ||
| Q1 25 | $35.5M | $45.1M | ||
| Q4 24 | $33.1M | $3.9M | ||
| Q3 24 | $53.9M | $9.1M | ||
| Q2 24 | $53.2M | $-24.7M |
自由现金流PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-13.3M | ||
| Q3 25 | $57.0M | $7.5M | ||
| Q2 25 | $9.3M | $10.4M | ||
| Q1 25 | $26.9M | $43.4M | ||
| Q4 24 | $31.0M | $2.1M | ||
| Q3 24 | $49.8M | $8.0M | ||
| Q2 24 | $51.6M | $-25.7M |
自由现金流率PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -4.1% | ||
| Q3 25 | 31.7% | 2.5% | ||
| Q2 25 | 5.1% | 3.4% | ||
| Q1 25 | 15.9% | 14.6% | ||
| Q4 24 | 16.6% | 0.7% | ||
| Q3 24 | 29.6% | 2.8% | ||
| Q2 24 | 29.0% | -9.1% |
资本支出强度PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 2.2% | 1.5% | ||
| Q2 25 | 1.5% | 0.7% | ||
| Q1 25 | 5.1% | 0.6% | ||
| Q4 24 | 1.1% | 0.6% | ||
| Q3 24 | 2.4% | 0.4% | ||
| Q2 24 | 0.9% | 0.4% |
现金转化率PCRXRVLV
| Q1 26 | — | — | ||
| Q4 25 | — | -0.55× | ||
| Q3 25 | 11.20× | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | 7.37× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | 2.82× | -1.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
